欧林生物
(688319)
| 流通市值：46.58亿 | | | 总市值：46.64亿 |
| 流通股本：4.05亿 | | | 总股本：4.06亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 192,461,037.43 | 235,746,602.08 | 293,322,800.83 | 362,070,721.55 |
| 应收票据及应收账款 | 529,695,793.14 | 494,800,187.2 | 474,554,566.45 | 491,548,299.06 |
| 其中：应收票据 | 1,300,000 | 3,276,700 | 300,000 | 300,000 |
| 应收账款 | 528,395,793.14 | 491,523,487.2 | 474,254,566.45 | 491,248,299.06 |
| 预付款项 | 7,646,201.85 | 7,792,878.25 | 7,239,731.2 | 4,190,923.52 |
| 其他应收款合计 | 1,903,555.3 | 1,701,866.49 | 2,289,475.42 | 1,098,673.76 |
| 存货 | 90,441,430.49 | 85,378,518.35 | 76,670,451.68 | 72,116,155.57 |
| 其他流动资产 | 541,086.7 | 900,806.65 | 1,146,993.33 | 164,880.13 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 899,689,104.91 | 886,320,859.02 | 884,224,118.91 | 931,189,753.59 |
| 非流动资产: | | | | |
| 固定资产 | 234,256,175.55 | 239,641,113.86 | 234,442,271.24 | 239,280,608.31 |
| 在建工程 | 287,438,539 | 248,795,869.87 | 225,533,056.25 | 181,354,692.02 |
| 使用权资产 | 2,463,724.71 | 3,387,621.49 | 4,311,518.27 | 5,235,415.05 |
| 无形资产 | 16,072,304.66 | 16,347,484.74 | 16,573,728.78 | 16,820,970.47 |
| 开发支出 | 244,849,665.04 | 241,435,947.43 | 200,496,254.13 | 186,095,079.93 |
| 长期待摊费用 | 7,147,943.73 | 7,988,067.64 | 8,854,058.72 | 9,666,203.6 |
| 递延所得税资产 | 14,074,469.69 | 14,074,469.69 | 14,074,469.69 | 14,074,469.69 |
| 其他非流动资产 | 1,585,900 | 6,143,937 | 5,627,800 | 28,888,572.43 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 807,888,722.38 | 777,814,511.72 | 709,913,157.08 | 681,416,011.5 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,707,577,827.29 | 1,664,135,370.74 | 1,594,137,275.99 | 1,612,605,765.09 |
| 流动负债: | | | | |
| 短期借款 | 24,200,000 | 29,200,000 | 29,200,000 | 24,200,000 |
| 应付票据及应付账款 | 45,486,330.89 | 54,123,602.69 | 44,965,832.5 | 40,055,652.89 |
| 应付账款 | 45,486,330.89 | 54,123,602.69 | 44,965,832.5 | 40,055,652.89 |
| 合同负债 | 363,354.91 | 702,290.29 | 958,566.67 | 3,621,969.15 |
| 应付职工薪酬 | 458,495.15 | 404,454.73 | 405,599.3 | 13,807,913.41 |
| 应交税费 | 4,589,786.21 | 3,449,454.75 | 5,237,422.05 | 6,743,089.04 |
| 其他应付款合计 | 329,486,410.92 | 327,454,320.01 | 308,770,942.01 | 355,992,044.96 |
| 一年内到期的非流动负债 | 79,230,000 | 69,550,000 | 31,690,000 | 31,690,000 |
| 其他流动负债 | 13,754.85 | 21,068.71 | 28,757 | 108,659.07 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 483,828,132.93 | 484,905,191.18 | 421,257,119.53 | 476,219,328.52 |
| 非流动负债: | | | | |
| 长期借款 | 273,941,528.4 | 256,241,528.4 | 238,942,181.4 | 177,288,381.4 |
| 租赁负债 | 1,601,496.81 | 2,553,530.79 | 3,495,295.9 | 4,426,902.91 |
| 预计负债 | 731,314.42 | 698,864.84 | 92,264.67 | 1,212,625.54 |
| 递延收益 | 23,809,716.3 | 24,503,325.97 | 19,944,142.08 | 19,977,819.81 |
| 递延所得税负债 | 2,715,170.53 | 2,715,170.53 | 2,715,170.53 | 2,715,170.53 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 302,799,226.46 | 286,712,420.53 | 265,189,054.58 | 205,620,900.19 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 786,627,359.39 | 771,617,611.71 | 686,446,174.11 | 681,840,228.71 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 405,933,600 | 406,158,300 | 406,158,300 | 406,158,300 |
| 资本公积 | 609,254,429.51 | 613,621,844.83 | 609,967,790.65 | 605,746,395.33 |
| 减:库存股 | 5,552,337 | 7,940,898 | 7,961,870 | 7,961,870 |
| 盈余公积 | 8,615,917.45 | 8,615,917.45 | 8,615,917.45 | 8,615,917.45 |
| 未分配利润 | -107,052,309.84 | -139,025,218.63 | -121,650,121.3 | -95,653,191.14 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 911,199,300.12 | 881,429,945.65 | 895,130,016.8 | 916,905,551.64 |
| 少数股东权益 | 9,751,167.78 | 11,087,813.38 | 12,561,085.08 | 13,859,984.74 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 920,950,467.9 | 892,517,759.03 | 907,691,101.88 | 930,765,536.38 |
| 负债和股东权益合计 | 1,707,577,827.29 | 1,664,135,370.74 | 1,594,137,275.99 | 1,612,605,765.09 |
| 公告日期 | 2024-10-30 | 2024-08-22 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |